FASN and intrahepatic cholangiocarcinoma: Notably, FASN inhibitors markedly enhance the therapeutic effect of PD-1 monoclonal antibodies in patients with intrahepatic cholangiocarcinoma (ICC) associated with liver fluke infection (44), presenting a promising new treatment strategy for liver fluke-related ICC.